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ABSTRACT The clinical course of lung transplantation (LT) is diverse: some patients present chronic
lung allograft dysfunction (CLAD) and progressive decline in pulmonary function, but others maintain
normal spirometric values and active lives.
Objectives: The aim of this study was to elucidate whether long-term LT survivors with normal
spirometry achieve normal exercise capacity, and to identify predictive factors of exercise capacity.
Methods: This was a cross-sectional multicentre study, where bilateral LT recipients who survived at least
10 years after LT, with normal spirometry, no diagnosis of CLAD and modified Medical Research Council
dyspnoea degree ⩽2 underwent cardiopulmonary exercise testing (CPET).
Results: 28 LT recipients were included with a mean±SD age of 48.7±13.6 years. Oxygen uptake (V′O2) had
a mean±SD value of 21.49±6.68 mL·kg−1·min−1 (75.24±15.6%) and the anaerobic threshold was reached at
48.6±10.1% of the V′O2max predicted. The mean±SD heart rate reserve at peak exercise was 17.56±13.6%.
The oxygen pulse increased during exercise and was within normal values at 90.5±19.4%. The respiratory
exchange ratio exceeded 1.19 at maximum exercise. The median (25–75th percentile) EuroQol-5D score was
1 (0.95–1), indicating a good quality of life. The median (25–75th percentile) International Physical Activity
Questionnaire score was 5497 (4007–9832) MET-min·week−1 with 89% of patients reporting more than
1500 MET-min·week−1. In the multivariate regression models, age, sex and diffusing capacity of the lung for
carbon monoxide remained significantly associated with V′O2max (mL·kg
−1·min−1); haemoglobin and forced
expiratory volume in 1 s were significantly associated with maximum work rate (watts), after adjusting for
confounders.
Conclusion: We report for the first time near-normal peak V′O2 values during CPET and normal exercise
capacity in long-term LT recipients without CLAD.
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Lung transplantation (LT) is an established treatment for end-stage respiratory diseases, which improves
patient’s health-related quality of life (HRQoL), especially in the physical functioning domains [1]. Despite
improvements in respiratory symptoms and pulmonary function, reports from the early 1990s showed a
reduction in peak oxygen uptake (V′O2) ranging between 44% and 59% in single LT, and between 40% and
50% in bilateral LT [2–6] with little or no improvement after 2 years of follow-up.
Transferring the results of these studies to the clinical field is difficult because of their small sample sizes,
evaluation of specific LT type, and the different timing of exercise testing and lung function. All the
authors that have previously addressed this topic share the view that LT recipients, either for intrinsic or
extrinsic reasons, do not reach normal oxygen consumption values. However, in our clinical experience,
while some patients develop chronic lung graft dysfunction and a progressive decline in lung function,
others attain normal spirometric values and are able to carry out considerable activities despite presenting
good exercise capacity [2–6]. The most common causes invoked to explain low exercise capacity, in spite
of the striking recovery of lung function after LT, are anaemia, cardiac and peripheral vascular factors,
impaired oxidative capacity of peripheral skeletal muscle, lower limb skeletal muscle dysfunction, muscle
weakness and sarcopenia [2, 7, 8]. The literature supporting these mechanisms is scarce and severe muscle
deconditioning (which could be reverted with time) is a very plausible additional explanation. To explore
this possibility, studies analysing exercise capacity and other exercise variables in the long term are needed.
As far as we know, such studies are lacking and as a result, obtaining definite conclusions regarding the
causes of exercise limitation in LT recipients remains a challenging task. Nevertheless, we hypothesise that
LT recipients with normal lung function and generally good health status could preserve near-normal
V′O2 values.
We therefore analysed exercise capacity in long-term survivors after bilateral LT with normal lung function
tests. Our aims were: 1) to establish whether these patients could achieve normal exercise capacity, and
2) to identify predictive factors of exercise capacity in this LT population.
Methods
Study design
A prospective cross-sectional study was performed in LT recipients recruited from six different LT referral
centres from all over Spain, between 2015 and 2016. The study was approved by the Institutional Ethics
Board (Vall d’Hebron Hospital, Barcelona, ID of approval: PR(AG)64/2015), and all the participants
provided signed informed consent.
Subjects
Inclusion criteria were: 1) bilateral LT conducted at least 10 years prior to the inclusion date; 2) normal
spirometry (forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) >80% and FEV1/FVC
ratio >0.7); 3) no diagnosis of chronic lung allograft dysfunction (CLAD); 4) ability to complete
cardiopulmonary exercise testing (CPET); and 5) dyspnoea degree 2 or lower on the modified Medical
Research Council score (mMRC).
Demographic and clinical data such as sex, age, smoking history, date of LT and current treatment were
recorded or obtained from medical records. Physical activity was measured with the long form of the
International Physical Activity Questionnaire (IPAQ), which calculates the total energy expenditure per
week (METs-min·week−1) from the time (in minutes) spent walking and performing moderate-intensity
and vigorous-intensity physical activity in four different domains (leisure time, domestic, work-related and
transport-related physical activity) [9]. HRQoL was assessed through the “EuroQol-5D” test [10], which
comprises five questions on mobility, self-care, pain, usual activities and psychological state.
All the tests were performed in the same centre (Hospital Universitari Vall d’Hebron), so the patients were
required to travel, if necessary.
Pulmonary function testing
All patients underwent forced spirometry, static lung volume study by plethysmography, and single-breath
lung diffusing capacity for carbon monoxide (DLCO) using the single breath-hold method (MasterLab,
Vyasisr, Hochburg Germany). These studies were performed following the recommendations of the
European [11] and Spanish Respiratory Societies [12].
Cardiopulmonary exercise testing
CPET was performed on a cycle ergometer using a breath-by-breath system (MEDGRAPHICS CPX, St
Paul, MN, USA). The speed of the ramp protocol was determined according to the maximum voluntary
ventilation (MVV): for MVV <40 L·min−1 at 10 W·min−1 and for MVV >40 L·min−1 at 15 W·min−1 [13],
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with this adjustment in our experience the test usually lasted between 10 and 15 min. After 3 min resting
and 3 min of unloaded pedalling, the workload was progressively increased in order to obtain a test lasting
8–12 min. Oxygen saturation and pulse rate was continuously monitored along the test. Breath-by-breath
the following features were recorded: V′O2, carbon dioxide output (V′CO2), minute ventilation (V′E), pulse
rate (PR), arterial blood pressure, dyspnoea, and leg fatigue (Borg). Subjects were asked to maintain a
pedalling cadence between 50 and 60 revolutions per min for the duration of the test. If cadence declined
and fell below 40 revolutions per min for longer than 5 s, the test was terminated [13].
Free-fat body mass measurement
Tissue composition analysis was performed by electrical bioimpedance equipment 50 Hz (BIA 101, Akern
Srl; Florence, Italy). Single-frequency bioelectrical impedance analysis was carried out with an impedance
plethysmograph that emitted 400 µA and 50 kHz alternating sinusoidal current and was connected to
surface electrodes (standard, tetrapolar placement on the right hand and foot) following the method
reported elsewhere [14].
Statistics
The results are expressed as absolute frequencies and percentages for qualitative variables, as mean±SD for
quantitative variables with a normal distribution, and as the median and interquartile range (IQR) for
quantitative variables with a non-normal distribution. The relationship between sociodemographic, clinical
and functional variables and exercise capacity was tested by means of a Chi-squared test, Fisher’s exact
test, t-test, Mann–Whitney U-test and Spearman’s correlation coefficient as appropriate. For variables
TABLE 1 Clinical characteristics of lung transplant (LT) recipients
Subjects n 29
Age years 48.7±13.6
Male sex n (%) 14 (48)
Age at the time of LT years 34.7±14.0











Arterial hypertension n (%) 15 (51.7)
Diabetes mellitus n (%) 6 (20.7)
Dyslipidaemia n (%) 11 (37.9)
Smoking history n (%)
Never smoked 21 (72.4)
Former smoker 8 (27.6)
Packs per year 29.7±23.4
Lung function
FVC L 3.9±0.92
FVC % predicted 92.6±15.7
FEV1 L 3.1±0.7
FEV1 % predicted 97.9±14.5
DLCO (mL·mmHg
−1·min−1) median (IQR) 77.1 (70–83.3)
TLC % predicted 96.1±18.3
RV % predicted 81.0±8.5
Oral corticosteroids n (%) 28 (96.6)
Oral corticosteroids dosage mg 3.9±1.6
Data are presented as mean±SD, unless otherwise stated. Some variables have missing values: eight in
FFMI, one in packs per year and one in corticosteroid dosage. ILD: interstitial lung disease; CF: cystic
fibrosis; PH: pulmonary hypertension; BMI: body mass index; FFMI: fat-free mass index; FVC: forced vital
capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide;
IQR: interquartile range; TLC: total lung capacity; RV: residual volume.
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significantly related to exercise performance, a stepwise multiple linear regression with a backward
elimination (entry threshold, p<0.05; removal threshold, p>0.10) was performed using V′O2 peak and work
rate (WR) peak as dependent variables. To avoid collinearity, we used the variable with the highest
correlation (r) with exercise capacity in bivariate regression analyses. Analyses were adjusted for age and
sex and goodness of fit was assessed by means of normality of residuals, heteroscedasticity, linearity,
collinearity and identification of influential data. Limits of significance were set at p<0.05. Data analysis
was conducted using Stata 12.1 (StataCorp, College Station, TX, USA).
Results
Subject characteristics
28 consecutive patients met the inclusion criteria and agreed to participate in this study. Six patients
declined to take part in the study due to travelling or competing commitments. Subject demographics are
shown in table 1. Mean±SD age was 48.7±13.6 years, and there was an equal distribution between men and
women. The majority of patients (48.3%) had cystic fibrosis (CF) as the underlying disease requiring LT,
normal body mass index and normal lean mass. Cardiovascular risk factors were seen in 51.7% of patients.
Regarding immunosuppressive treatment, 79% of patients were receiving tacrolimus (mean blood level
8.6 ng·mL−1), 20% cyclosporine (mean blood level 181.2 ng·mL−1), 66% mycophenolate (mean dosage
1087 mg·day−1) and 28% azathioprine (mean dosage 62.5 mg·day−1). 28 patients out of 29 were on oral
steroids at a mean±SD dose of 3.89±1.57 mg.
Metabolic response to exercise
V′O2 peak, WR, heart rate (HR), heart rate reserve (HRR), O2 pulse, and respiratory exchange ratio (RER)
during exercise are shown in table 2. V′O2 had a mean value of 21.49±6.68 mL·kg−1·min−1 (75.24±15.6%
of predicted value) and the anaerobic threshold was reached at 48.6±10.1% of predicted value. There were
no differences between males and females or CF and non-CF patients (data not shown).
Circulatory response to exercise
The mean±SD HRR at peak exercise was 17.56±13.6%. The O2 pulse increased during exercise in all
patients and was within normal values, at 90.5±19.4%. The RER exceeded 1.19 in all patients at maximum
exercise. The mean±SD peak venous blood lactate level was 7.35±1.89 mmol·L−1 (table 2).
Ventilatory and gas exchange response to exercise
Table 2 shows the ventilatory and gas exchange variables during exercise. The median (IQR) peak V′E was
54 (48–67.1) L·min−1. Maximum V′E averaged 52% (48–57) of the calculated MVV. The median (IQR)
TABLE 2 Exercise capacity, physical activity and quality of life of lung transplant (LT) recipients
Subjects n 29
V′O2 peak mL·kg−1·min−1 21.49±6.68
V′O2 peak % pred 75.24±15.6
V′O2 AT % 48.6±10.1
V′CO2 peak L·min−1 median (IQR) 1.68 (1.43–2.06)
Work peak watts 111.14±37.13
V′E/V′CO2 AT 32 (31–35)
V′E peak L·min−1 median (IQR) 54 (48–67.1)
RER peak median (IQR) 1.35 (1.25–1.4)
HR peak beats·min−1 141.5±21.4
HRR peak 17.5±13.6
V′O2/HR 90.5±19.4
VR peak median (IQR) 52 (48–57)
Oximetry at V′O2 max % 97.6±0.8
Lactic acid peak mmol·L−1 7.35±1.89
IPAQ METs-min·week−1 median (IQR) 5497 (4007–9832)
Euroqol 5-D 1 (0.95–1)
Euroqol >0.8 29±100
Data are presented as mean±SD, unless otherwise stated.V′O2: oxygen uptake; V′CO2: carbon dioxide output;
IQR: interquartile range; AT: aerobic threshold; V′E: minute ventilation; RER: respiratory exchange ratio;
HR: heart rate; HRR: heart rate reserve; VR: ventilator reserve; IPAQ: International Physical Activity
Questionnaire.
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value for V′E/ V′CO2 at ventilatory threshold was 32 (31–35). The oxygen saturation was normal at peak
exercise in all individuals.
HRQoL and physical activity
The median (25–75th percentile) EuroQol- 5D score was 1 (0.95–1), showing a good quality of life in all
subjects.
The median (25–75th percentile) IPAQ score was 5497 (4007–9832) MET-min·week−1, with the majority
of patients (89%) reporting >1500 MET-min·week−1.
Correlations and adjusted analysis to predict peak V′O2 and peak WR
There was a positive correlation between peak V′O2 (mL·kg
−1·min−1) and haemoglobin (Hb) values
(r=0.555; p=0.002), basal FVC (L) (r=0.571; p=0.001), FEV1 (L) (r=0.675; p<0.001), DLCO (% pred)
(r=0.656; p<0.001) and a negative correlation between V′O2 (mL·kg
−1·min−1) and age (years) (r=−0.491;
p=0.007). There was a positive correlation between V′O2 (% pred) and FVC (% pred) (r=0.421; p=0.023),
FEV1 (% pred) (r=0.414; p=0.026), total lung capacity (% pred) (r=0.427; p=0.021) and DLCO (% pred)
(r=0.569; p=0.002). Peak WR correlated positively with Hb (g·dL−1) and FEV1 (L) (r=0.525; p=0.004 and
r=0.616; p<0.001, respectively) and negatively with age (years) (r=−0.469; p=0.010) (figures 1 and 2).
In the multivariate regression models (table 3), only age, sex and DLCO remained significantly associated
with peak V′O2 (mL·kg−1·min−1); and Hb and FEV1 with peak WR (watts), after adjusting for
confounders. Linear regression goodness of fit tests did not reveal any abnormality.
The adjusted predicted peak V′O2 value (and 95% confidence interval) was plotted against DLCO (figure 3)
and shows that the higher the DLCO value, the greater the exercise capacity, in a linear dose–response
manner. Likewise, figure 4 depicts the adjusted linear dose–response WR peak (watts) predicted values
(and 95% confidence intervals) according to Hb (g·dL−1).
Discussion
In this study long-term LT survivors with preserved lung function presented a mean peak V′O2 value of
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FIGURE 1 Correlations between peak oxygen uptake (V′O2peak) (% predicted) and a) forced expiratory volume
in 1 s (FEV1) (% predicted), b) forced vital capacity (FVC) (% predicted), c) total lung capacity (TLC) (%
predicted) and d) diffusing capacity of the lungs for carbon monoxide (DLCO) (% predicted).
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regression model revealed significant associations between age, sex and DLCO and peak V′O2
(mL·kg−1·min−1), and between Hb and FEV1 and peak WR (watts), after adjusting for confounders. The
median (25–75th percentile) EuroQol-5D score was 1 (0.95–1), indicating a good quality of life in all
subjects.
During the 1990s, several authors reported small samples of LT patients with peak V′O2 values ranging
between 38% and 60% of the maximum predicted value [2–5, 15]. Later, BARTELS et al. [7] described a
sample of 78 bilateral LT recipients recruited between 2001 and 2009 who presented a mean peak V′O2
value of 52% of the maximum predicted value 30 months after LT. Recently, ULVESTAD et al. [16] reported
a peak V′O2 of 57% and 70% for men and women, respectively, in a sample of 54 patients in a period
ranging from 6 to 60 months after bilateral LT . In the present study the mean peak V′O2 value was 75.24%
of the maximum predicted value, indicating a much higher exercise capacity than in previous studies.
These findings need to be framed in the context of a highly active subpopulation, although it should not
be undermined that this study proves that even in selected LT recipients, near-normal peak V′O2 values are
achievable after undergoing LT.
Like BARTELS et al. [7], we observed no cardiac or ventilatory limitations. Although in both studies all
patients presented normal FEV1, in the study by BARTELS et al., the mean DLCO value was 57% while ours
was 77.5%. Similarly, MIYOSHI et al. [3] described a mean V′O2 peak value of 48.5% in six double-LT
patients undergoing CPET in a range between 6 and 48.5 months after surgery. While the six patients
presented normal FEV1 and DLCO values after LT, they had a mean Hb value of 10.8 mg·dL
−1; therefore,
the authors suggested anaemia as the main cause for exercise limitation. SCHWAIBLMAIR et al. [4] also
reported peripheral deficiencies in oxygen transport as the major cause of exercise limitation in 32 bilateral
LT recipients undergoing CPET within 3 months of LT. These patients presented a mean peak V′O2 of
40.2% of the predicted value along with mean FEV1 and DLCO values of 66.6% and 69.4%, respectively and
also a mean Hb of 10.9 g·dL−1. The positive correlation between the peak V′O2 value (mL·kg
−1·min−1) and
Hb and the inverse correlation between peak V′O2 and age found in the present study suggests that these
factors are crucial and determine exercise capacity in LT recipients. Indeed, in our study the stepwise
multiple regression analysis for peak workload revealed anaemia as an independent predictor. Medication
200
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FIGURE 2 Correlations between maximum work rate (WRmax) (watts) and a) age, b) haemoglobin (Hb) and c) forced expiratory volume in 1 s (FEV1)
(L).
TABLE 3 Results of stepwise multiple regression analysis for maximal oxygen uptake
(V′O2max) and maximum workload
V′O2max mL·kg−1·min−1 Maximum workload watts
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Age years −0.249 (−0.37–−0.13) <0.001 −0.24 (−1.17–0.69) 0.599
Male sex 5.35 (2.19–8.51) 0.002 4.72 (−34.75–25.30) 0.748
Haemoglobin g·dL−1 9.62 (2.21–17.02) 0.013
FEV1 L 31.53 (8.88–54.17) 0.008
DLCO % predicted 0.26 (0.15–0.36) <0.001
Constant 18.87 (16.80–20.95) <0.001
Adjusted R2 0.685 0.580
FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide.
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effects, immune-mediated factors and various forms of haemolysis may all contribute to developing
anaemia, which can affect oxygen transport and tissue extraction even in mild cases [16].
In agreement with previous findings, we recorded a positive correlation between peak V′O2 (mg·kg
−1·min−1
and %, respectively) and pulmonary function values. The stepwise multiple regression analysis for peak
V′O2 (mL·kg
−1·min−1) showed DLCO (% predicted) as an independent predictor. In a process such as
bilateral LT in which histological alterations reduce the area of gas exchange, it is plausible to think that
the determination most able to predict V′O2 max is DLCO. In fact, in other processes such as idiopathic
pulmonary fibrosis [17] or COPD [18], which like bilateral LT, show falls in these parameters and
hypoxaemia and respiratory insufficiency in advanced stages, there is a growing consensus that DLCO
should be added not only for patient diagnosis and management but also for the evaluation of the
response to new drugs in clinical trials. In this regard, and also in relation to DLCO, the stepwise multiple
regression analysis for peak WR (watts) identified Hb (mg·mL−1) as an independent predictor of peak
V′O2. Although these results suggest that small changes in DLCO might significantly impact % V′O2 max
values, they should be cautiously interpreted and confirmation in other studies is needed.
There is no standard inventory for formally evaluating HRQoL in transplant medicine. However, several
authors have reported significant improvement in almost all HRQoL domains in the first 3 years after
transplant [19–22]. VERMUELEN et al. [23] described HRQoL comparable with that in the general
population after LT although they observed a fall over time in relation to the rising incidence of
bronchiolitis obliterans syndrome and comorbid conditions. However, there are few studies analysing
HRQoL in long-term LT survivors. Other authors [23–25] reported significantly reduced HRQoL in the
main domains in LT recipients surviving periods ranging from 5 to 10 years. The median (25–75th
percentile) EuroQol-5D score in the present study was 1 (0.95–1), indicating a good quality of life in all
subjects. These findings contrast with those described by previous authors, although the differences are
most likely to be related to the study entry criteria.
FIGURE 3 Adjusted predicted
maximal oxygen uptake (V′O2max)
values (and 95% confidence
interval) against diffusing capacity






















FIGURE 4 Adjusted predicted
maximum work rate (WRmax) values
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Regarding physical activity, notable improvements with regard to pre-transplant symptoms have been
reported by several studies [26–28]. Over time, however, many LT recipients reported new symptoms
related to limb muscle dysfunction (muscle atrophy, muscle weakness and changes in muscle composition
and metabolism) and other comorbidities. The LT recipients in our study presented a median (25–75th
percentile) IPAQ score of 5497 (4007–9832) MET-min·week−1, and most (89%) reported more than
1500 MET-min·week−1. All reported a high amount of activity in the five domains analysed. Again, these
findings may be related to the particular characteristics of our study population. Without doubt the high
amount of daily activity could reflect a training effect, despite these patients not following any specific
training programme before entering the study. Thus, these results would highlight the importance of
physical activity as a bridge to obtain a good aerobic capacity, as has been glimpsed in other studies [29].
This study has several strengths. It assesses a single long-term LT patient sample recruited from all over
Spain, and the CPET was performed in the same time window and in identical conditions. Likewise,
patients underwent not only CEPT but also a comprehensive measurement of other relevant factors such
as lean body mass index and completed the IPAQ and EUROQol-5D questionnaires, which allow further
analysis of little-known peripheral deficiencies.
The main limitation of this study is the highly selected sample of LT recipients. Long-term survivors after
LT with normal spirometry are uncommon. Although it has not been possible to know the exact number
of long-term survivors in Spain, in our centre 4% of all bilateral LT performed survived for 10 years with
normal spirometry. Thus, in Spain, from 1124 bilateral LT performed during this period, we estimate that
44 patients would fulfil the criteria to take part in this study (www.ont.es). We think our sample is
representative enough, if we take into account that the study required travelling for many patients.
Another related limitation is the high amount of daily activity performed by these patients, which could be
related to the preservation of the aerobic capacity, beyond the normal lung function. Despite the fact that
the population sample of the current study may not be widely representative, the main outcome was to
elucidate whether in the best scenario the LT recipients would be able to achieve normal aerobic capacity.
Finally, we do not have information on quadriceps strength, which is a strong correlate of exercise capacity
and which would have helped us to describe this population in more detail.
In conclusion, this is, to our knowledge, the first study to describe near-normal V′O2 peak values during
CPET and normal aerobic capacity in long-term LT patients. Only age, sex and DLCO remained
significantly associated with V′O2 peak (mL·kg
−1·min−1) after adjusting for confounders. The stepwise
multiple regression analysis for workload peak revealed anaemia as an independent factor. All the patients
included in the study presented a good quality of life and a high exercise capacity.
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